<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:44:34Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9973272" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9973272</identifier>
        <datestamp>2023-03-01</datestamp>
        <setSpec>mbio</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="brief-report">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">mBio</journal-id>
              <journal-id journal-id-type="iso-abbrev">mBio</journal-id>
              <journal-id journal-id-type="publisher-id">mbio</journal-id>
              <journal-title-group>
                <journal-title>mBio</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2150-7511</issn>
              <publisher>
                <publisher-name>American Society for Microbiology</publisher-name>
                <publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9973272</article-id>
              <article-id pub-id-type="pmcid">PMC9973272</article-id>
              <article-id pub-id-type="pmc-uid">9973272</article-id>
              <article-id pub-id-type="pmid">36625657</article-id>
              <article-id pub-id-type="pmid">36625657</article-id>
              <article-id pub-id-type="publisher-id">03287-22</article-id>
              <article-id pub-id-type="doi">10.1128/mbio.03287-22</article-id>
              <article-id pub-id-type="publisher-id">mbio.03287-22</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Observation</subject>
                </subj-group>
                <subj-group subj-group-type="biological-terms">
                  <compound-subject>
                    <compound-subject-part content-type="code">virology</compound-subject-part>
                    <compound-subject-part content-type="label">Virology</compound-subject-part>
                  </compound-subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2785-317X</contrib-id>
                  <name>
                    <surname>Karaba</surname>
                    <given-names>Andrew H.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                  <!--<xref ref-type="other" rid="cr1 cr2 cr3 cr4 cr5 cr6 cr7 cr8 cr9"/>-->
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Johnston</surname>
                    <given-names>Trevor S.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                  <!--<xref ref-type="other" rid="cr10 cr11 cr12 cr13 cr14 cr15"/>-->
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Beck</surname>
                    <given-names>Evan</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                  <!--<xref ref-type="other" rid="cr16 cr17 cr18 cr19 cr20 cr21"/>-->
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6429-4760</contrib-id>
                  <name>
                    <surname>Laeyendecker</surname>
                    <given-names>Oliver</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">
                    <sup>b</sup>
                  </xref>
                  <!--<xref ref-type="other" rid="cr22 cr23 cr24 cr25 cr26 cr27"/>-->
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cox</surname>
                    <given-names>Andrea L.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                  <!--<xref ref-type="other" rid="cr28 cr29 cr30"/>-->
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0730-5224</contrib-id>
                  <name>
                    <surname>Klein</surname>
                    <given-names>Sabra L.</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">
                    <sup>c</sup>
                  </xref>
                  <!--<xref ref-type="other" rid="cr31 cr32 cr33"/>-->
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0319-0578</contrib-id>
                  <name>
                    <surname>Sullivan</surname>
                    <given-names>David J.</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">
                    <sup>c</sup>
                  </xref>
                  <email>dsulliv7@jhmi.edu</email>
                  <!--<xref ref-type="other" rid="cr34 cr35 cr36 cr37 cr38 cr39 cr40 cr41 cr42"/>-->
                </contrib>
                <contrib contrib-type="author">
                  <collab>COVID-19 Serologic Studies Consortium</collab>
                </contrib>
                <aff id="aff1">
                  <label>a</label>
                  <addr-line>Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</addr-line>
                </aff>
                <aff id="aff2">
                  <label>b</label>
                  <addr-line>Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Baltimore, Maryland, USA</addr-line>
                </aff>
                <aff id="aff3">
                  <label>c</label>
                  <addr-line>The Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA</addr-line>
                </aff>
              </contrib-group>
              <contrib-group>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Meisenberg</surname>
                    <given-names>Barry R.</given-names>
                  </name>
                  <aff>Anne Arundel Medical Center</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Abinante</surname>
                    <given-names>Matthew</given-names>
                  </name>
                  <aff>Ascada Research</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Oei</surname>
                    <given-names>Kevin</given-names>
                  </name>
                  <aff>Ascada Research</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Fukuta</surname>
                    <given-names>Yuriko</given-names>
                  </name>
                  <aff>Baylor College of Medicine</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Kessaye</surname>
                    <given-names>Seble</given-names>
                  </name>
                  <aff>MedStar Georgetown University Hospital</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Hammitt</surname>
                    <given-names>Laura L.</given-names>
                  </name>
                  <aff>Johns Hopkins Center for American Indian Health</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Sutcliffe</surname>
                    <given-names>Catherine G.</given-names>
                  </name>
                  <aff>Johns Hopkins Center for American Indian Health</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Sullivan</surname>
                    <given-names>David J.</given-names>
                  </name>
                  <aff>Johns Hopkins Bloomberg School of Public Health</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Lau</surname>
                    <given-names>Bryan</given-names>
                  </name>
                  <aff>Johns Hopkins Bloomberg School of Public Health</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Singh</surname>
                    <given-names>Atika</given-names>
                  </name>
                  <aff>Johns Hopkins Bloomberg School of Public Health</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Shade</surname>
                    <given-names>David M.</given-names>
                  </name>
                  <aff>Johns Hopkins Bloomberg School of Public Health</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Ehrhardt</surname>
                    <given-names>Stephan</given-names>
                  </name>
                  <aff>Johns Hopkins Bloomberg School of Public Health</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Baksh</surname>
                    <given-names>Sheriza N.</given-names>
                  </name>
                  <aff>Johns Hopkins Bloomberg School of Public Health</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Pekosz</surname>
                    <given-names>Andrew</given-names>
                  </name>
                  <aff>Johns Hopkins Bloomberg School of Public Health</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Klein</surname>
                    <given-names>Sabra L.</given-names>
                  </name>
                  <aff>Johns Hopkins Bloomberg School of Public Health</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Casadevall</surname>
                    <given-names>Arturo</given-names>
                  </name>
                  <aff>Johns Hopkins Bloomberg School of Public Health</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Gebo</surname>
                    <given-names>Kelly A</given-names>
                  </name>
                  <aff>Johns Hopkins University</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Shoham</surname>
                    <given-names>Shmuel</given-names>
                  </name>
                  <aff>Johns Hopkins University</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Bloch</surname>
                    <given-names>Evan M.</given-names>
                  </name>
                  <aff>Johns Hopkins University</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Marshall</surname>
                    <given-names>Christi E.</given-names>
                  </name>
                  <aff>Johns Hopkins University</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Yarava</surname>
                    <given-names>Anusha</given-names>
                  </name>
                  <aff>Johns Hopkins University</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Lane</surname>
                    <given-names>Karen</given-names>
                  </name>
                  <aff>Johns Hopkins University</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>McBee</surname>
                    <given-names>Nichol A.</given-names>
                  </name>
                  <aff>Johns Hopkins University</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Gawad</surname>
                    <given-names>Amy L.</given-names>
                  </name>
                  <aff>Johns Hopkins University</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Karlen</surname>
                    <given-names>Nicky</given-names>
                  </name>
                  <aff>Johns Hopkins University</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Ford</surname>
                    <given-names>Daniel E.</given-names>
                  </name>
                  <aff>Johns Hopkins University</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Jabs</surname>
                    <given-names>Douglas A.</given-names>
                  </name>
                  <aff>Johns Hopkins University</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Appel</surname>
                    <given-names>Lawrence J.</given-names>
                  </name>
                  <aff>Johns Hopkins University</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Tobian</surname>
                    <given-names>Aaron A.R.</given-names>
                  </name>
                  <aff>Johns Hopkins University</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Hanley</surname>
                    <given-names>Daniel F.</given-names>
                  </name>
                  <aff>Johns Hopkins University</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Levine</surname>
                    <given-names>Adam C.</given-names>
                  </name>
                  <aff>Lifespan/Brown University Rhode Island Hospital</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Blair</surname>
                    <given-names>Janis E.</given-names>
                  </name>
                  <aff>Mayo Clinic, Phoenix</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Shenoy</surname>
                    <given-names>Aarthi</given-names>
                  </name>
                  <aff>MedStar Washington Hospital Center</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Mosnaim</surname>
                    <given-names>Giselle S.</given-names>
                  </name>
                  <aff>NorthShore University HealthSystem</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Gniadek</surname>
                    <given-names>Thomas J.</given-names>
                  </name>
                  <aff>NorthShore University HealthSystem</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Roth</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <aff>The Bliss Group</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Foster</surname>
                    <given-names>Colin</given-names>
                  </name>
                  <aff>The Next Practice Group</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Currier</surname>
                    <given-names>Judith S.</given-names>
                  </name>
                  <aff>University of California Los Angeles</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Health</surname>
                    <given-names>Sonya L.</given-names>
                  </name>
                  <aff>University of Alabama at Birmingham</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Forthal</surname>
                    <given-names>Donald N.</given-names>
                  </name>
                  <aff>University of California, Irvine Health</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Cachay</surname>
                    <given-names>Edward R.</given-names>
                  </name>
                  <aff>University of California, San Diego</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Allen</surname>
                    <given-names>Elizabeth S.</given-names>
                  </name>
                  <aff>University of California, San Diego</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Huaman</surname>
                    <given-names>Moises A.</given-names>
                  </name>
                  <aff>University of Cincinnati Medical Center</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Gerber</surname>
                    <given-names>Jonathan M.</given-names>
                  </name>
                  <aff>University of Massachusetts Worcester</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Anjan</surname>
                    <given-names>Shweta</given-names>
                  </name>
                  <aff>University of Miami</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Raval</surname>
                    <given-names>Jay S.</given-names>
                  </name>
                  <aff>University of New Mexico</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Zand</surname>
                    <given-names>Martin S.</given-names>
                  </name>
                  <aff>University of Rochester</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Patel</surname>
                    <given-names>Bela</given-names>
                  </name>
                  <aff>University of Texas Health Science Center at Houston</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Spivak</surname>
                    <given-names>Emily S.</given-names>
                  </name>
                  <aff>University of Utah Health</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Singleton</surname>
                    <given-names>J. Robinson</given-names>
                  </name>
                  <aff>University of Utah Health</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Cluzet</surname>
                    <given-names>Valerie C.</given-names>
                  </name>
                  <aff>Vassar Brothers Medical Center</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Cruser</surname>
                    <given-names>Daniel</given-names>
                  </name>
                  <aff>Vassar Brothers Medical Center</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Paxton</surname>
                    <given-names>James H.</given-names>
                  </name>
                  <aff>Wayne State University</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Petrini</surname>
                    <given-names>Joann R.</given-names>
                  </name>
                  <aff>Western Connecticut Health Network, Danbury Hospital</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Broderick</surname>
                    <given-names>Patrick B.</given-names>
                  </name>
                  <aff>Western Connecticut Health Network, Danbury Hospital</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Rausch</surname>
                    <given-names>William</given-names>
                  </name>
                  <aff>Western Connecticut Health Network, Danbury Hospital</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Cordisco</surname>
                    <given-names>MarieElena</given-names>
                  </name>
                  <aff>Western Connecticut Health Network, Danbury Hospital</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Hammel</surname>
                    <given-names>Jean</given-names>
                  </name>
                  <aff>Western Connecticut Health Network, Norwalk Hospital</aff>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Greenblatt</surname>
                    <given-names>Benjamin</given-names>
                  </name>
                  <aff>Western Connecticut Health Network, Norwalk Hospital</aff>
                </contrib>
              </contrib-group>
              <contrib-group>
                <contrib contrib-type="editor">
                  <role>Editor</role>
                  <name>
                    <surname>Pirofski</surname>
                    <given-names>Liise-anne</given-names>
                  </name>
                  <aff>Albert Einstein College of Medicine</aff>
                </contrib>
              </contrib-group>
              <author-notes>
                <fn fn-type="COI-statement">
                  <p>The authors declare a conflict of interest. The authors report no competing interests to this work. A.H.K. reports receiving consulting fees from Roche. D.J.S. reports AliquantumRx Founder and Board member with stock options (macrolide for malaria), Hemex Health malaria diagnostics consulting and royalties for malaria diagnostic test control standards to Alere- all outside of submitted work.</p>
                </fn>
              </author-notes>
              <pub-date publication-format="electronic" date-type="pub">
                <day>10</day>
                <month>1</month>
                <year>2023</year>
              </pub-date>
              <pub-date publication-format="electronic" date-type="collection">
                <season>Jan-Feb</season>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>10</day>
                <month>1</month>
                <year>2023</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>14</volume>
              <issue>1</issue>
              <elocation-id>e03287-22</elocation-id>
              <history>
                <date date-type="received">
                  <day>30</day>
                  <month>11</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>1</day>
                  <month>12</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright © 2023 Karaba et al.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <copyright-holder>Karaba et al.</copyright-holder>
                <ali:free_to_read start_date="2023-01-10"/>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="mbio.03287-22.pdf"/>
              <abstract>
                <title>ABSTRACT</title>
                <p>The impact of preexisting antibodies to the four endemic human coronaviruses (ehCoV) (229E, OC43, NL63, and HKU1) on severe (hospitalization) coronavirus disease 2019 (COVID-19) outcomes has been described in small cohorts. Many studies have measured ehCoV 229E, OC43, NL63, and HKU1 antibody levels weeks after recovery rather than in the first weeks of illness, which is more relevant to early hospitalizations. Antibody levels to the spike protein of the four coronaviruses (229E, OC43, NL63, and HKU1), as well as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were measured both before and immediately after convalescent or control plasma transfusion in 51 participants who were hospitalized and 250 who were not hospitalized, as well as in 71 convalescent and 50 control plasma donors as a subset from a completed randomized controlled trial. In COVID-19 convalescent plasma donors, the ehCoV spike antibodies were 1.2 to 2 times greater than the control donor unit levels, while donor COVID-19 convalescent plasma (CCP) SARS-CoV-2 spike antibodies were more than 600 times the control plasma units. Plasma transfusion, whether COVID-19 convalescent or control, did not alter the post-transfusion antibody levels for the endemic human coronaviruses (229E, OC43, NL63, and HKU1) in those hospitalized and not hospitalized, despite the 1.2- to 2-fold elevation in donor COVID-19 convalescent plasma. There was no influence of prior antibody levels to 229E, OC43, NL63, and HKU1 or post-transfusion antibody levels on subsequent hospitalization. These data, from a well-controlled prospective randomized clinical trial, add evidence that antibodies to ehCoV do not significantly impact COVID-19 outcomes, despite the apparent back-boosting of some ehCoV after SARS-CoV-2 infection.</p>
              </abstract>
              <kwd-group>
                <title>KEYWORDS</title>
                <kwd>COVID-19</kwd>
                <kwd>SARS-CoV-2</kwd>
                <kwd>endemic human coronaviruses</kwd>
                <kwd>plasma transfusion</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group award-type="grant" id="award1">
                  <funding-source id="GS1">
                    <institution-wrap>
                      <institution>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000060</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>3R01AI152078</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Sullivan</surname>
                      <given-names>David J.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group award-type="grant" id="award2">
                  <funding-source id="GS2">
                    <institution-wrap>
                      <institution>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000060</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>K08AI156021</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Karaba</surname>
                      <given-names>Andrew H.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group award-type="grant" id="award3">
                  <funding-source id="GS3">
                    <institution-wrap>
                      <institution>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000060</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R01AI138897</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Karaba</surname>
                      <given-names>Andrew H.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group award-type="grant" id="award4">
                  <funding-source id="GS4">
                    <institution-wrap>
                      <institution>U.S. Department of Defense (DOD)</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000005</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>W911QY2090012</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Sullivan</surname>
                      <given-names>David J.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group award-type="grant" id="award5">
                  <funding-source id="GS5">
                    <institution-wrap>
                      <institution>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>U54CA260491</award-id>
                  <principal-award-recipient><name><surname>Klein</surname><given-names>Sabra L.</given-names></name>, <name><surname>Cox</surname><given-names>Andrea L.</given-names></name></principal-award-recipient>
                </award-group>
              </funding-group>
              <counts>
                <count count="9" count-type="supplementary-material"/>
                <fig-count count="2"/>
                <table-count count="0"/>
                <equation-count count="0"/>
                <ref-count count="15"/>
                <page-count count="7"/>
                <word-count count="4957"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>January/February 2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="s1">
              <title>OBSERVATION</title>
              <p>The influence of preexisting antibodies to the four endemic human coronaviruses (ehCoV) (229E, OC43, NL63, and HKU1) on severe (hospitalization) coronavirus disease 2019 (COVID-19) outcomes has not been fully characterized (<xref rid="B1" ref-type="bibr">1</xref>). COVID-19 convalescent plasma (CCP) obtained weeks after illness contains higher IgG levels to the four ehCoV than pre-COVID-19 control plasma (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>). Recovered convalescent individuals with severe COVID-19 also have higher antibody levels to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as a boosted response to the four ehCoV (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). SARS-CoV-2 vaccination also boosts ehCoV antibodies (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). Most studies measure ehCoV antibody levels weeks after symptom onset instead of in the first week of illness (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B5" ref-type="bibr">5</xref>). Some studies implicate the cross-reactive protection of ehCoV antibodies (<xref rid="B8" ref-type="bibr">8</xref>). Pre-COVID-19 plasma has been shown to neutralize SARS-CoV-2 (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>). Recent endemic human coronavirus infection was also associated with less severe COVID-19 (<xref rid="B11" ref-type="bibr">11</xref>).</p>
              <p>The prospective association of severe COVID-19 with elevated ehCoV antibody levels at illness onset has not been investigated (<xref rid="B12" ref-type="bibr">12</xref>). A clinically relevant question was raised recently as to whether antibody levels to ehCoV in control plasma as opposed to saline could deleteriously influence hospital outcomes in controls during a clinical trial (<xref rid="B13" ref-type="bibr">13</xref>). The literature has mainly looked retrospectively for correlations of high antibody levels weeks after hospitalization, even though COVID-19 hospitalization itself raises antibody levels to both ehCoV and SARS-CoV-2 (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>).</p>
              <p>This substudy of a larger trial (<xref rid="B14" ref-type="bibr">14</xref>) focuses on the impact of preexisting ehCoV antibody immunity on the outcome of severe SARS-CoV-2 disease by measuring ehCoV antibody levels in the first week of COVID-19, rather than taking a retrospective look back weeks after recovery. Additionally, we examined ehCoV and SARS-CoV-2 antibody levels from unused CCP and nonconvalescent control donor units, as well as before and after randomized transfusion (within the first 9 days of COVID-19), in a representative sampling of participants from a subset of an interventional randomized clinical trial, which demonstrated efficacy at outpatient hospital reduction (<xref rid="B14" ref-type="bibr">14</xref>).</p>
              <p>Antibodies that bind the spike proteins from 229E, NL63, OC43, HKU1, and SARS-CoV-2 were measured using the Meso Scale Diagnostics (MSD; Rockville, MD) V-PLEX COVID-19 coronavirus panel 3 IgG kit at a dilution of 1:5,000. Plates were read on a Meso QuickPlex SQ 120 instrument, and the arbitrary units (AU) were calculated using the MSD Discovery Workbench software according to the manufacturer’s protocol. For the samples in the spike competition experiment, purified recombinant full-length WA-1 SARS-CoV-2 spike protein (150 μg/mL) (<xref rid="B4" ref-type="bibr">4</xref>) was incubated 1:1 with plasma samples for 45 min prior to antibody measurement via the MSD assay as described above. Approvals were obtained from the institutional review boards at Johns Hopkins University School of Medicine under a single IRB (IRB00247590) for all participating sites and the Department of Defense (DoD) Human Research Protection Office. All the trial participants provided written informed consent for the scope of this research.</p>
              <p>The nonhospitalized subset (<italic toggle="yes">n</italic> = 250) randomly chosen for endemic human CoV antibody analysis was similar to the full study with regard to key demographic features. This subgroup had a similar percentage of female participants, with similar comorbidities (hypertension, lung disease, diabetes) and a small 4-year mean age difference (see <xref rid="tabS1" ref-type="supplementary-material">Table S1</xref> in the supplemental material). SARS-CoV-2 vaccination at enrollment was excluded for this substudy.</p>
              <supplementary-material position="float" id="tabS1" content-type="local-data">
                <object-id pub-id-type="doi">10.1128/mbio.03287-22.9</object-id>
                <label>TABLE S1</label>
                <p>Characteristics of substudy participants compared to those in the parent study (<xref rid="B14" ref-type="bibr">14</xref>). Download <inline-supplementary-material id="tS1" xlink:href="mbio.03287-22-s0009.docx" content-type="local-data">Table S1, DOCX file, 0.02 MB</inline-supplementary-material>.</p>
                <permissions>
                  <copyright-statement>Copyright © 2023 Karaba et al.</copyright-statement>
                  <copyright-year>2023</copyright-year>
                  <copyright-holder>Karaba et al.</copyright-holder>
                  <ali:free_to_read start_date="2023-01-10"/>
                  <license license-type="open-access">
                    <ali:license_ref specific-use="version-of-record">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                    <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                  </license>
                </permissions>
              </supplementary-material>
              <p>In CCP donors, the ehCoV spike antibodies were 1.2 to 2 times greater than the control donor unit levels, while the donor CCP SARS-CoV-2 spike antibodies were more than 600 times the levels of the control units (<xref rid="fig1" ref-type="fig">Fig. 1A</xref>). In the SARS-CoV-2 CCP participants who were seronegative for the SARS-CoV-2 receptor-binding domain (RBD) by Euroimmun assay, the SARS-CoV-2 spike antibodies increased 17-fold from pretransfusion screen to post-transfusion, while the HKU1 and OC43 antibodies showed a small insignificant increase. In separate seronegative control recipients, the ehCoV antibodies pretransfusion to post-transfusion were also unchanged (<xref rid="fig1" ref-type="fig">Fig. 1B</xref>, <xref rid="fig1" ref-type="fig">C</xref>). We also measured antibody levels pre- and post-transfusion in 50 participants who were seropositive at enrollment (<xref rid="figS1" ref-type="supplementary-material">Fig. S1A</xref>, <xref rid="figS1" ref-type="supplementary-material">B</xref>). Baseline pretransfusion SARS-CoV-2, HKU1, and OC43 antibody levels in seropositive CCP and controls were increased compared to seronegative participants, with no change post-transfusion for all viruses. In the hospitalized CCP and control plasma participants, the pretransfusion and post-transfusion geometric mean antibody levels were similar, except for SARS-CoV-2 in CCP recipients (<xref rid="fig2" ref-type="fig">Fig. 2A</xref>, <xref rid="fig2" ref-type="fig">B</xref>). A comparison of pretransfusion antibody levels in all 51 hospitalized participants to the levels in those not hospitalized indicated no differences in ehCoV levels (<xref rid="fig2" ref-type="fig">Fig. 2C</xref>).</p>
              <fig position="float" id="fig1">
                <label>FIG 1</label>
                <caption>
                  <p>ehCoV antibody levels in donors and nonhospitalized recipients in the early treatment outpatient CCP study. (A) Coronavirus antibody levels (arbitrary units [AU] per milliliter) shown in donor CCP (red circles; <italic toggle="yes">n</italic> = 71) and control plasma (blue circles; <italic toggle="yes">n</italic> = 50) units. CCP ehCoV antibodies were 1.2 to 2 times higher than in control plasma units. SARS-CoV-2 antibody levels were more than 600 times higher in CCP than in control units. (B) Coronavirus antibody levels before and 30 min after transfusion of CCP among participants who were negative for SARS-CoV-2 RBD at enrollment (red circles; <italic toggle="yes">n</italic> = 100). (C) Coronavirus antibody levels before and 30 min after transfusion of control plasma among participants who were negative for SARS-CoV-2 RBD at enrollment (blue circles; <italic toggle="yes">n</italic> = 100). ehCoV antibody levels were similar before and 30 min after transfusion for those transfused with CCP or control plasma. Horizontal black bars represent geometric means. Statistically significant 2-way analysis of variance (ANOVA) (Tukey <italic toggle="yes">post hoc</italic>) of log-transformed values indicated by brackets. <italic toggle="yes">P</italic> values of &lt;0.05 were considered significant. **, <italic toggle="yes">P</italic> = 0.001, ***, <italic toggle="yes">P</italic> = 0.0004, ****, <italic toggle="yes">P</italic> &lt; 0.0001.</p>
                </caption>
                <graphic xlink:href="mbio.03287-22-f001" position="anchor"/>
              </fig>
              <fig position="float" id="fig2">
                <label>FIG 2</label>
                <caption>
                  <p>Endogenous human coronavirus (ehCoV) antibody levels in hospitalized participants in the early treatment outpatient CCP study. (A) Antibody levels (AU per milliliter) before and 30 min after transfusion of CCP in participants who were eventually hospitalized (red circles; <italic toggle="yes">n</italic> = 17). (B) Antibody levels in participants who received control plasma and were eventually hospitalized (blue circles; <italic toggle="yes">n</italic> = 34). Except for a SARS-CoV-2 spike in the CCP recipients, all before and after transfusion antibody levels were similar. (C) Antibody levels at time of enrollment in participants who were hospitalized (<italic toggle="yes">n</italic> = 51; orange circles) were compared with antibody levels at enrollment for nonhospitalized participants (<italic toggle="yes">n</italic> = 250; green). No significant differences were observed. Geometric means are indicated with horizontal black bars. Brackets between groups indicate statistically significant differences as determined by 2-way ANOVA (Tukey <italic toggle="yes">post hoc</italic>) of log-transformed values. <italic toggle="yes">P</italic> values of &lt;0.05 were considered significant. ****, <italic toggle="yes">P</italic> &lt; 0.0001.</p>
                </caption>
                <graphic xlink:href="mbio.03287-22-f002" position="anchor"/>
              </fig>
              <supplementary-material position="float" id="figS1" content-type="local-data">
                <object-id pub-id-type="doi">10.1128/mbio.03287-22.1</object-id>
                <label>FIG S1</label>
                <p>(A) Coronavirus antibody levels (AU/mL) before and 30 min after transfusion of CCP in participants who were seropositive for SARS-CoV-2 RBD prior to transfusion (<italic toggle="yes">n</italic> = 25; red). (B) Coronavirus antibody levels (AU/mL) before and 30 min after transfusion of control plasma in participants who were seropositive for SARS-CoV-2 RBD prior to transfusion (<italic toggle="yes">n</italic> = 25; blue). There were no statistically significant differences in any coronavirus antibodies before and after transfusion by a 2-way ANOVA (Tukey <italic toggle="yes">post hoc</italic>) of log-transformed values. <italic toggle="yes">P</italic> values of &lt;0.05 were considered significant. Download <inline-supplementary-material id="fS1" xlink:href="mbio.03287-22-s0001.docx" content-type="local-data">FIG S1, DOCX file, 0.1 MB</inline-supplementary-material>.</p>
                <permissions>
                  <copyright-statement>Copyright © 2023 Karaba et al.</copyright-statement>
                  <copyright-year>2023</copyright-year>
                  <copyright-holder>Karaba et al.</copyright-holder>
                  <ali:free_to_read start_date="2023-01-10"/>
                  <license license-type="open-access">
                    <ali:license_ref specific-use="version-of-record">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                    <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                  </license>
                </permissions>
              </supplementary-material>
              <p>The increase in convalescent antibody levels against HKU1 and OC43 seen in this study, both of which are also betacoronaviruses, might be from cross-reactivity with elevated SARS-CoV-2 spike antibodies or induction of ehCoV-specific B cells to generate more ehCoV antibodies. We added purified SARS-CoV-2 spike at 150 μg spike/mL plasma (<xref rid="B4" ref-type="bibr">4</xref>) to donor unit plasma samples. SARS-CoV-2-specific antibodies were reduced 86% and HKU1 by 21%, suggesting minimal measurable cross-reactivity with HKU1 spike only (<xref rid="figS2" ref-type="supplementary-material">Fig. S2</xref>).</p>
              <supplementary-material position="float" id="figS2" content-type="local-data">
                <object-id pub-id-type="doi">10.1128/mbio.03287-22.2</object-id>
                <label>FIG S2</label>
                <p>Competition of antibody signal with recombinant SARS-CoV-2 full-length spike protein: 13 donor units (red, no competition) were preincubated with 150 mcg recombinant WA-1 SARS-CoV-2 spike (<xref rid="B4" ref-type="bibr">4</xref>) per milliliter of plasma, followed by antibody level determination (black, competition). SARS-CoV-2 was significantly reduced by 86%, while HKU1 was nonsignificantly reduced by 21%, and 229E, NL63, and OC43 were unchanged. Download <inline-supplementary-material id="fS2" xlink:href="mbio.03287-22-s0002.docx" content-type="local-data">FIG S2, DOCX file, 0.1 MB</inline-supplementary-material>.</p>
                <permissions>
                  <copyright-statement>Copyright © 2023 Karaba et al.</copyright-statement>
                  <copyright-year>2023</copyright-year>
                  <copyright-holder>Karaba et al.</copyright-holder>
                  <ali:free_to_read start_date="2023-01-10"/>
                  <license license-type="open-access">
                    <ali:license_ref specific-use="version-of-record">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                    <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                  </license>
                </permissions>
              </supplementary-material>
              <p>Heterogeneity heat maps of antibody levels sorted by 229E indicated similar patterns among those hospitalized to those not hospitalized (<xref rid="figS3" ref-type="supplementary-material">Fig. S3</xref>). The donor CCP and control plasma had similar antibody levels despite regional donations (<xref rid="figS4" ref-type="supplementary-material">Fig. S4</xref>). Despite minimum ongoing ehCoV transmission due to social isolation measures during the trial, over time the remnant donor CCP and control plasma, as well as, in participants, the four ehCoV antibody levels, were the same over the more than 12 months of the study (<xref rid="figS5" ref-type="supplementary-material">Fig. S5</xref> to <xref rid="figS8" ref-type="supplementary-material">S8</xref>). We observed no significant post-transfusion ehCoV antibody level changes in either the CCP or control plasma recipients to account for intervention arm differences in hospitalization from either ehCoV antibody COVID-19 cross-protection or enhancement. Many other studies measured 229E, OC43, NL63, and HKU1 antibody levels weeks after illness rather than during the first week of illness. The first week of illness had a higher predictive value on early hospitalizations, which mostly happened within a week of transfusion or within 2 weeks of illness onset.</p>
              <supplementary-material position="float" id="figS3" content-type="local-data">
                <object-id pub-id-type="doi">10.1128/mbio.03287-22.3</object-id>
                <label>FIG S3</label>
                <p>Heterogeneity of viral antibody levels at the individual level with arbitrary units per milliliter depicted on log scale. (A) Antibody levels at enrollment (screening) for the 50 participants who were hospitalized, including those who received CCP or control plasma, sorted ascending by measured 229E. (B) Screening antibody levels for the 50 antibody-positive, vaccine-negative participants, including those who received CCP or control plasma, sorted ascending by measured 229E. (C) Screening antibody levels for the 100 antibody-negative, vaccine-negative participants who received control plasma, sorted ascending by measured 229E. (D) Screening antibody levels for the 100 antibody-negative, vaccine-negative participants who received CCP, sorted ascending by measured 229E. Download <inline-supplementary-material id="fS3" xlink:href="mbio.03287-22-s0003.docx" content-type="local-data">FIG S3, DOCX file, 0.2 MB</inline-supplementary-material>.</p>
                <permissions>
                  <copyright-statement>Copyright © 2023 Karaba et al.</copyright-statement>
                  <copyright-year>2023</copyright-year>
                  <copyright-holder>Karaba et al.</copyright-holder>
                  <ali:free_to_read start_date="2023-01-10"/>
                  <license license-type="open-access">
                    <ali:license_ref specific-use="version-of-record">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                    <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                  </license>
                </permissions>
              </supplementary-material>
              <supplementary-material position="float" id="figS4" content-type="local-data">
                <object-id pub-id-type="doi">10.1128/mbio.03287-22.4</object-id>
                <label>FIG S4</label>
                <p>CCP and control plasma donors segregated by region of donation by the 4 ehCoV. CCP are indicated by red circles and control plasma by blue circles. CCP: Washington DC and Maryland (<italic toggle="yes">n</italic> = 20), Iowa and Illinois (<italic toggle="yes">n</italic> = 13), and New York and New Jersey (<italic toggle="yes">n</italic> = 38). Control plasma: Washington DC (<italic toggle="yes">n</italic> = 45) and New Jersey (<italic toggle="yes">n</italic> = 5). Download <inline-supplementary-material id="fS4" xlink:href="mbio.03287-22-s0004.docx" content-type="local-data">FIG S4, DOCX file, 0.1 MB</inline-supplementary-material>.</p>
                <permissions>
                  <copyright-statement>Copyright © 2023 Karaba et al.</copyright-statement>
                  <copyright-year>2023</copyright-year>
                  <copyright-holder>Karaba et al.</copyright-holder>
                  <ali:free_to_read start_date="2023-01-10"/>
                  <license license-type="open-access">
                    <ali:license_ref specific-use="version-of-record">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                    <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                  </license>
                </permissions>
              </supplementary-material>
              <supplementary-material position="float" id="figS5" content-type="local-data">
                <object-id pub-id-type="doi">10.1128/mbio.03287-22.5</object-id>
                <label>FIG S5</label>
                <p>Individual CCP donors, sorted by date of donation during the collection period of the early treatment trial from 1 May to 30 September, for 229E (A), HKU1 (B), NL63 (C), and OC43 (D), with arbitrary units (AU) shown per milliliter. Download <inline-supplementary-material id="fS5" xlink:href="mbio.03287-22-s0005.docx" content-type="local-data">FIG S5, DOCX file, 0.09 MB</inline-supplementary-material>.</p>
                <permissions>
                  <copyright-statement>Copyright © 2023 Karaba et al.</copyright-statement>
                  <copyright-year>2023</copyright-year>
                  <copyright-holder>Karaba et al.</copyright-holder>
                  <ali:free_to_read start_date="2023-01-10"/>
                  <license license-type="open-access">
                    <ali:license_ref specific-use="version-of-record">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                    <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                  </license>
                </permissions>
              </supplementary-material>
              <p>The antibody levels of ehCoV in COVID-19 convalescent plasma were only 2-fold different between the control and convalescent plasma. The volume of distribution of the plasma was 3 to 6 L. The measured fold dilution when transfused into healthy individuals was 25-fold with a 200-mL CCP transfusion (<xref rid="B15" ref-type="bibr">15</xref>). When plasma with ehCoV antibodies was diluted 20-fold, it resulted in no change before or after transfusion, as shown here in over 300 paired samples, of which 51 donors were later hospitalized. Likewise, in those clinical trial recipients who were SARS-CoV-2 antibody negative or positive, there was no change in the levels before or after transfusion, but those who were seropositive for SARS CoV-2 at enrollment had HKU1 and OC43 levels that were twice as high compared to the seronegative participant ehCoV levels, which mirrored the levels seen in donor CCP compared to control plasma, with only the 2-fold difference, which, again, did not change the post-transfusion antibody levels.</p>
              <p>Measurement of the available 17 hospitalized participants in the COVID-19 convalescent plasma arm and the 34 in the control plasma arm indicated no absolute ehCoV antibody level differences between these two groups or with 250 other paired participants. Even combining all 51 hospitalized participants to compare them to the 250 participants not hospitalized at screening before transfusion showed no differences.</p>
              <p>In this study, the EhCoV antibody levels of those hospitalized and those not hospitalized were not distinguishable during the first week of illness, at which time there exists greatest risk for impact on severe COVID-19 outcome. Thus, it is unlikely that preexisting ehCoV antibodies in plasma have any clinically relevant impact on COVID-19 outcomes.</p>
            </sec>
            <sec id="s2">
              <sec disp-level="2" id="s2-1">
                <title>Data availability.</title>
                <p>The data sets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.</p>
                <supplementary-material position="float" id="figS6" content-type="local-data">
                  <object-id pub-id-type="doi">10.1128/mbio.03287-22.6</object-id>
                  <label>FIG S6</label>
                  <p>Individual control plasma, sorted by date of donation during the collection period of the early treatment trial from 1 May to 30 September, for 229E (A), HKU1 (B), NL63 (C), and OC43 (D), with arbitrary units (AU) shown per milliliter. Download <inline-supplementary-material id="fS6" xlink:href="mbio.03287-22-s0006.docx" content-type="local-data">FIG S6, DOCX file, 0.07 MB</inline-supplementary-material>.</p>
                  <permissions>
                    <copyright-statement>Copyright © 2023 Karaba et al.</copyright-statement>
                    <copyright-year>2023</copyright-year>
                    <copyright-holder>Karaba et al.</copyright-holder>
                    <ali:free_to_read start_date="2023-01-10"/>
                    <license license-type="open-access">
                      <ali:license_ref specific-use="version-of-record">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                      <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                    </license>
                  </permissions>
                </supplementary-material>
                <supplementary-material position="float" id="figS7" content-type="local-data">
                  <object-id pub-id-type="doi">10.1128/mbio.03287-22.7</object-id>
                  <label>FIG S7</label>
                  <p>Participants randomized to CCP with screening antibodies for ehCoV, sorted by date of enrollment during the collection period of the early treatment trial from 1 May to 30 September, for 229E (A), HKU1 (B), NL63 (C), and OC43 (D), with arbitrary units (AU) shown per milliliter. Download <inline-supplementary-material id="fS7" xlink:href="mbio.03287-22-s0007.docx" content-type="local-data">FIG S7, DOCX file, 0.1 MB</inline-supplementary-material>.</p>
                  <permissions>
                    <copyright-statement>Copyright © 2023 Karaba et al.</copyright-statement>
                    <copyright-year>2023</copyright-year>
                    <copyright-holder>Karaba et al.</copyright-holder>
                    <ali:free_to_read start_date="2023-01-10"/>
                    <license license-type="open-access">
                      <ali:license_ref specific-use="version-of-record">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                      <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                    </license>
                  </permissions>
                </supplementary-material>
                <supplementary-material position="float" id="figS8" content-type="local-data">
                  <object-id pub-id-type="doi">10.1128/mbio.03287-22.8</object-id>
                  <label>FIG S8</label>
                  <p>Participants randomized to control plasma with screening antibodies against ehCoV, sorted by date of enrollment during the collection period of the early treatment trial from 1 May to 30 September, for 229E (A), HKU1 (B), NL63 (C), and OC43 (D), with arbitrary units (AU) shown per milliliter. Download <inline-supplementary-material id="fS8" xlink:href="mbio.03287-22-s0008.docx" content-type="local-data">FIG S8, DOCX file, 0.1 MB</inline-supplementary-material>.</p>
                  <permissions>
                    <copyright-statement>Copyright © 2023 Karaba et al.</copyright-statement>
                    <copyright-year>2023</copyright-year>
                    <copyright-holder>Karaba et al.</copyright-holder>
                    <ali:free_to_read start_date="2023-01-10"/>
                    <license license-type="open-access">
                      <ali:license_ref specific-use="version-of-record">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                      <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
                    </license>
                  </permissions>
                </supplementary-material>
              </sec>
            </sec>
          </body>
          <back>
            <ack>
              <title>ACKNOWLEDGMENTS</title>
              <p>A. H. Karaba and D. J. Sullivan had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p>
              <p>S. L. Klein, A. L. Cox, A. H. Karaba, and D. J. Sullivan contributed to the conceptualization and design. All authors contributed to acquisition, analysis, or interpretation of the data. A. H. Karaba and D. J. Sullivan drafted the manuscript; all authors critically revised the manuscript for important intellectual content. A. H. Karaba, T. S. Johnston, and D. J. Sullivan conducted the statistical analysis. D. J. Sullivan obtained funding. A. H. Karaba, T. S. Johnston, E. Beck, O. Laeyendecker, and D. J. Sullivan contributed administrative, technical, or material support. A. H. Karaba and D. J. Sullivan supervised the research.</p>
              <p>This study was funded principally by the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency (DHA) (contract number W911QY2090012), with additional support from Bloomberg Philanthropies, State of Maryland, the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) (3R01AI152078-01S1, K08AI156021, U54CA260491, and R01AI138897), the NIH National Cancer Institute (NCI) (U54CA260491), the NIH National Center for Advancing Translational Sciences (NCATS) (U24TR001609-S3), the Division of Intramural Research NIAID NIH, the Mental Wellness Foundation, the Moriah Fund, Octapharma, the Healthnetwork Foundation, and the Shear Family Foundation. The study sponsors did not contribute to the study design, the collection, analysis, and interpretation of data, or the decision to submit the paper for publication.</p>
              <p>We report no competing interests to this work. A. H. Karaba reports receiving consulting fees from Roche. D. J. Sullivan reports that he is an AliquantumRx founder and board member with stock options (macrolide for malaria), works for Hemex Health malaria diagnostics consulting, and receives royalties for malaria diagnostic test control standards from Alere—all outside the submitted work.</p>
              <p>The members of the COVID-10 Serologic Studies Consortium are as follows: Barry R. Meisenberg (Anne Arundel Medical Center), Matthew Abinante (Ascada Research), Kevin Oei (Ascada Research), Yuriko Fukuta (Baylor College of Medicine), Seble Kessaye (MedStar Georgetown University Hospital), Laura L. Hammitt (Johns Hopkins Center for American Indian Health), Catherine G. Sutcliffe (Johns Hopkins Center for American Indian Health), Bryan Lau (Johns Hopkins Bloomberg School of Public Health), Atika Singh (Johns Hopkins Bloomberg School of Public Health), David M. Shade (Johns Hopkins Bloomberg School of Public Health), Stephan Ehrhardt (Johns Hopkins Bloomberg School of Public Health), Sheriza N. Baksh (Johns Hopkins Bloomberg School of Public Health), Andrew Pekosz (Johns Hopkins Bloomberg School of Public Health), Arturo Casadevall (Johns Hopkins Bloomberg School of Public Health), Kelly A Gebo (Johns Hopkins University), Shmuel Shoham (Johns Hopkins University), Evan M. Bloch (Johns Hopkins University), Christi E. Marshall (Johns Hopkins University), Anusha Yarava (Johns Hopkins University), Karen Lane (Johns Hopkins University), Nichol A. McBee (Johns Hopkins University), Amy L. Gawad (Johns Hopkins University), Nicky Karlen (Johns Hopkins University), Daniel E. Ford (Johns Hopkins University), Douglas A. Jabs (Johns Hopkins University), Lawrence J. Appel (Johns Hopkins University), Aaron A.R. Tobian (Johns Hopkins University), Daniel F. Hanley (Johns Hopkins University), Adam C. Levine (Lifespan/Brown University Rhode Island Hospital), Janis E. Blair (Mayo Clinic, Phoenix), Aarthi Shenoy (MedStar Washington Hospital Center), Giselle S. Mosnaim (NorthShore University HealthSystem), Thomas J. Gniadek (NorthShore University HealthSystem), Michael Roth (The Bliss Group), Colin Foster (The Next Practice Group), Judith S. Currier (University of California Los Angeles), Sonya L. Health (University of Alabama at Birmingham), Donald N. Forthal (University of California, Irvine Health), Edward R. Cachay (University of California, San Diego), Elizabeth S. Allen (University of California, San Diego), Moises A. Huaman (University of Cincinnati Medical Center), Jonathan M. Gerber (University of Massachusetts Worcester), Shweta Anjan (University of Miami), Jay S. Raval (University of New Mexico), Martin S. Zand (University of Rochester), Bela Patel (University of Texas Health Science Center at Houston), Emily S. Spivak (University of Utah Health), J. Robinson Singleton (University of Utah Health), Valerie C. Cluzet (Vassar Brothers Medical Center), Daniel Cruser (Vassar Brothers Medical Center), James H. Paxton (Wayne State University), Joann R. Petrini (Western Connecticut Health Network, Danbury Hospital), Patrick B. Broderick (Western Connecticut Health Network, Danbury Hospital), William Rausch (Western Connecticut Health Network, Danbury Hospital), MarieElena Cordisco (Western Connecticut Health Network, Danbury Hospital), Jean Hammel (Western Connecticut Health Network, Norwalk Hospital), Benjamin Greenblatt (Western Connecticut Health Network, Norwalk Hospital).</p>
            </ack>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="B1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wells</surname><given-names>DA</given-names></string-name>, <string-name><surname>Cantoni</surname><given-names>D</given-names></string-name>, <string-name><surname>Mayora-Neto</surname><given-names>M</given-names></string-name>, <string-name><surname>Genova</surname><given-names>CD</given-names></string-name>, <string-name><surname>Sampson</surname><given-names>A</given-names></string-name>, <string-name><surname>Ferrari</surname><given-names>M</given-names></string-name>, <string-name><surname>Carnell</surname><given-names>G</given-names></string-name>, <string-name><surname>Nadesalingam</surname><given-names>A</given-names></string-name>, <string-name><surname>Smith</surname><given-names>P</given-names></string-name>, <string-name><surname>Chan</surname><given-names>A</given-names></string-name>, <string-name><surname>Raddi</surname><given-names>G</given-names></string-name>, <string-name><surname>Castillo-Olivares</surname><given-names>J</given-names></string-name>, <string-name><surname>Baxendale</surname><given-names>H</given-names></string-name>, <string-name><surname>Temperton</surname><given-names>N</given-names></string-name>, <string-name><surname>Heeney</surname><given-names>JL</given-names></string-name></person-group>. <year>2022</year>. <article-title>Human seasonal coronavirus neutralization and COVID-19 severity</article-title>. <source>J Med Virol</source> doi:<pub-id pub-id-type="doi">10.1002/jmv.27937</pub-id>.</mixed-citation>
              </ref>
              <ref id="B2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Adams</surname><given-names>O</given-names></string-name>, <string-name><surname>Andree</surname><given-names>M</given-names></string-name>, <string-name><surname>Rabl</surname><given-names>D</given-names></string-name>, <string-name><surname>Ostermann</surname><given-names>PN</given-names></string-name>, <string-name><surname>Schaal</surname><given-names>H</given-names></string-name>, <string-name><surname>Lehnert</surname><given-names>E</given-names></string-name>, <string-name><surname>Ackerstaff</surname><given-names>S</given-names></string-name>, <string-name><surname>Muller</surname><given-names>L</given-names></string-name>, <string-name><surname>Fischer</surname><given-names>JC</given-names></string-name></person-group>. <year>2022</year>. <article-title>Humoral response to SARS-CoV-2 and seasonal coronaviruses in COVID-19 patients</article-title>. <source>J Med Virol</source><volume>94</volume>:<fpage>1096</fpage>–<lpage>1103</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jmv.27427</pub-id>.<pub-id pub-id-type="pmid">34716706</pub-id></mixed-citation>
              </ref>
              <ref id="B3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morgenlander</surname><given-names>WR</given-names></string-name>, <string-name><surname>Henson</surname><given-names>SN</given-names></string-name>, <string-name><surname>Monaco</surname><given-names>DR</given-names></string-name>, <string-name><surname>Chen</surname><given-names>A</given-names></string-name>, <string-name><surname>Littlefield</surname><given-names>K</given-names></string-name>, <string-name><surname>Bloch</surname><given-names>EM</given-names></string-name>, <string-name><surname>Fujimura</surname><given-names>E</given-names></string-name>, <string-name><surname>Ruczinski</surname><given-names>I</given-names></string-name>, <string-name><surname>Crowley</surname><given-names>AR</given-names></string-name>, <string-name><surname>Natarajan</surname><given-names>H</given-names></string-name>, <string-name><surname>Butler</surname><given-names>SE</given-names></string-name>, <string-name><surname>Weiner</surname><given-names>JA</given-names></string-name>, <string-name><surname>Li</surname><given-names>MZ</given-names></string-name>, <string-name><surname>Bonny</surname><given-names>TS</given-names></string-name>, <string-name><surname>Benner</surname><given-names>SE</given-names></string-name>, <string-name><surname>Balagopal</surname><given-names>A</given-names></string-name>, <string-name><surname>Sullivan</surname><given-names>D</given-names></string-name>, <string-name><surname>Shoham</surname><given-names>S</given-names></string-name>, <string-name><surname>Quinn</surname><given-names>TC</given-names></string-name>, <string-name><surname>Eshleman</surname><given-names>SH</given-names></string-name>, <string-name><surname>Casadevall</surname><given-names>A</given-names></string-name>, <string-name><surname>Redd</surname><given-names>AD</given-names></string-name>, <string-name><surname>Laeyendecker</surname><given-names>O</given-names></string-name>, <string-name><surname>Ackerman</surname><given-names>ME</given-names></string-name>, <string-name><surname>Pekosz</surname><given-names>A</given-names></string-name>, <string-name><surname>Elledge</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>M</given-names></string-name>, <string-name><surname>Tobian</surname><given-names>AAR</given-names></string-name>, <string-name><surname>Larman</surname><given-names>HB</given-names></string-name></person-group>. <year>2021</year>. <article-title>Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality</article-title>. <source>J Clin Invest</source><volume>131</volume>:<elocation-id>e146927</elocation-id>. doi:<pub-id pub-id-type="doi">10.1172/JCI146927</pub-id>.<pub-id pub-id-type="pmid">33571169</pub-id></mixed-citation>
              </ref>
              <ref id="B4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Klein</surname><given-names>S</given-names></string-name>, <string-name><surname>Pekosz</surname><given-names>A</given-names></string-name>, <string-name><surname>Park</surname><given-names>H-S</given-names></string-name>, <string-name><surname>Ursin</surname><given-names>RL</given-names></string-name>, <string-name><surname>Shapiro</surname><given-names>JR</given-names></string-name>, <string-name><surname>Benner</surname><given-names>SE</given-names></string-name>, <string-name><surname>Littlefield</surname><given-names>K</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>S</given-names></string-name>, <string-name><surname>Naik</surname><given-names>HM</given-names></string-name>, <string-name><surname>Betenbaugh</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Shrestha</surname><given-names>R</given-names></string-name>, <string-name><surname>Wu</surname><given-names>AA</given-names></string-name>, <string-name><surname>Hughes</surname><given-names>RM</given-names></string-name>, <string-name><surname>Burgess</surname><given-names>I</given-names></string-name>, <string-name><surname>Caturegli</surname><given-names>P</given-names></string-name>, <string-name><surname>Laeyendecker</surname><given-names>O</given-names></string-name>, <string-name><surname>Quinn</surname><given-names>TC</given-names></string-name>, <string-name><surname>Sullivan</surname><given-names>D</given-names></string-name>, <string-name><surname>Shoham</surname><given-names>S</given-names></string-name>, <string-name><surname>Redd</surname><given-names>AD</given-names></string-name>, <string-name><surname>Bloch</surname><given-names>EM</given-names></string-name>, <string-name><surname>Casadevall</surname><given-names>A</given-names></string-name>, <string-name><surname>Tobian</surname><given-names>AA</given-names></string-name></person-group>. <year>2020</year>. <article-title>Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population</article-title>. <source>J Clin Invest</source><volume>130</volume>:<fpage>6141</fpage>–<lpage>6150</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI142004</pub-id>.<pub-id pub-id-type="pmid">32764200</pub-id></mixed-citation>
              </ref>
              <ref id="B5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ortega</surname><given-names>N</given-names></string-name>, <string-name><surname>Ribes</surname><given-names>M</given-names></string-name>, <string-name><surname>Vidal</surname><given-names>M</given-names></string-name>, <string-name><surname>Rubio</surname><given-names>R</given-names></string-name>, <string-name><surname>Aguilar</surname><given-names>R</given-names></string-name>, <string-name><surname>Williams</surname><given-names>S</given-names></string-name>, <string-name><surname>Barrios</surname><given-names>D</given-names></string-name>, <string-name><surname>Alonso</surname><given-names>S</given-names></string-name>, <string-name><surname>Hernandez-Luis</surname><given-names>P</given-names></string-name>, <string-name><surname>Mitchell</surname><given-names>RA</given-names></string-name>, <string-name><surname>Jairoce</surname><given-names>C</given-names></string-name>, <string-name><surname>Cruz</surname><given-names>A</given-names></string-name>, <string-name><surname>Jimenez</surname><given-names>A</given-names></string-name>, <string-name><surname>Santano</surname><given-names>R</given-names></string-name>, <string-name><surname>Mendez</surname><given-names>S</given-names></string-name>, <string-name><surname>Lamoglia</surname><given-names>M</given-names></string-name>, <string-name><surname>Rosell</surname><given-names>N</given-names></string-name>, <string-name><surname>Llupia</surname><given-names>A</given-names></string-name>, <string-name><surname>Puyol</surname><given-names>L</given-names></string-name>, <string-name><surname>Chi</surname><given-names>J</given-names></string-name>, <string-name><surname>Melero</surname><given-names>NR</given-names></string-name>, <string-name><surname>Parras</surname><given-names>D</given-names></string-name>, <string-name><surname>Serra</surname><given-names>P</given-names></string-name>, <string-name><surname>Pradenas</surname><given-names>E</given-names></string-name>, <string-name><surname>Trinite</surname><given-names>B</given-names></string-name>, <string-name><surname>Blanco</surname><given-names>J</given-names></string-name>, <string-name><surname>Mayor</surname><given-names>A</given-names></string-name>, <string-name><surname>Barroso</surname><given-names>S</given-names></string-name>, <string-name><surname>Varela</surname><given-names>P</given-names></string-name>, <string-name><surname>Vilella</surname><given-names>A</given-names></string-name>, <string-name><surname>Trilla</surname><given-names>A</given-names></string-name>, <string-name><surname>Santamaria</surname><given-names>P</given-names></string-name>, <string-name><surname>Carolis</surname><given-names>C</given-names></string-name>, <string-name><surname>Tortajada</surname><given-names>M</given-names></string-name>, <string-name><surname>Izquierdo</surname><given-names>L</given-names></string-name>, <string-name><surname>Angulo</surname><given-names>A</given-names></string-name>, <string-name><surname>Engel</surname><given-names>P</given-names></string-name>, <string-name><surname>Garcia-Basteiro</surname><given-names>AL</given-names></string-name>, <string-name><surname>Moncunill</surname><given-names>G</given-names></string-name>, <string-name><surname>Dobano</surname><given-names>C</given-names></string-name></person-group>. <year>2021</year>. <article-title>Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses</article-title>. <source>Nat Commun</source><volume>12</volume>:<fpage>4740</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-021-24979-9</pub-id>.<pub-id pub-id-type="pmid">34362897</pub-id></mixed-citation>
              </ref>
              <ref id="B6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lawrenz</surname><given-names>J</given-names></string-name>, <string-name><surname>Xie</surname><given-names>Q</given-names></string-name>, <string-name><surname>Zech</surname><given-names>F</given-names></string-name>, <string-name><surname>Weil</surname><given-names>T</given-names></string-name>, <string-name><surname>Seidel</surname><given-names>A</given-names></string-name>, <string-name><surname>Krnavek</surname><given-names>D</given-names></string-name>, <string-name><surname>van der Hoek</surname><given-names>L</given-names></string-name>, <string-name><surname>Munch</surname><given-names>J</given-names></string-name>, <string-name><surname>Muller</surname><given-names>JA</given-names></string-name>, <string-name><surname>Kirchhoff</surname><given-names>F</given-names></string-name></person-group>. <year>2022</year>. <article-title>Severe acute respiratory syndrome coronavirus 2 vaccination boosts neutralizing activity against seasonal human coronaviruses</article-title>. <source>Clin Infect Dis</source><volume>75</volume>:<fpage>e653</fpage>–<lpage>e661</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciac057</pub-id>.<pub-id pub-id-type="pmid">35079775</pub-id></mixed-citation>
              </ref>
              <ref id="B7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shapiro</surname><given-names>JR</given-names></string-name>, <string-name><surname>Sitaras</surname><given-names>I</given-names></string-name>, <string-name><surname>Park</surname><given-names>HS</given-names></string-name>, <string-name><surname>Aytenfisu</surname><given-names>TY</given-names></string-name>, <string-name><surname>Caputo</surname><given-names>C</given-names></string-name>, <string-name><surname>Li</surname><given-names>M</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J</given-names></string-name>, <string-name><surname>Johnston</surname><given-names>TS</given-names></string-name>, <string-name><surname>Li</surname><given-names>H</given-names></string-name>, <string-name><surname>Wouters</surname><given-names>C</given-names></string-name>, <string-name><surname>Hauk</surname><given-names>P</given-names></string-name>, <string-name><surname>Jacobsen</surname><given-names>H</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name><surname>Abrams</surname><given-names>E</given-names></string-name>, <string-name><surname>Yoon</surname><given-names>S</given-names></string-name>, <string-name><surname>Kocot</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Yang</surname><given-names>T</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Cramer</surname><given-names>SM</given-names></string-name>, <string-name><surname>Betenbaugh</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Debes</surname><given-names>AK</given-names></string-name>, <string-name><surname>Morgan</surname><given-names>R</given-names></string-name>, <string-name><surname>Milstone</surname><given-names>AM</given-names></string-name>, <string-name><surname>Karaba</surname><given-names>AH</given-names></string-name>, <string-name><surname>Pekosz</surname><given-names>A</given-names></string-name>, <string-name><surname>Leng</surname><given-names>SX</given-names></string-name>, <string-name><surname>Klein</surname><given-names>SL</given-names></string-name></person-group>. <year>2022</year>. <article-title>Association of frailty, age, and biological sex with severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine-induced immunity in older adults</article-title>. <source>Clin Infect Dis</source><volume>75</volume>:<fpage>S61</fpage>–<lpage>S71</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciac397</pub-id>.<pub-id pub-id-type="pmid">35607747</pub-id></mixed-citation>
              </ref>
              <ref id="B8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Waterlow</surname><given-names>NR</given-names></string-name>, <string-name><surname>van Leeuwen</surname><given-names>E</given-names></string-name>, <string-name><surname>Davies</surname><given-names>NG</given-names></string-name>, <string-name><surname>Flasche</surname><given-names>S</given-names></string-name>, <string-name><surname>Eggo</surname><given-names>RM</given-names></string-name>, <collab>CMMID COVID-19 Working Group</collab></person-group>. <year>2021</year>. <article-title>How immunity from and interaction with seasonal coronaviruses can shape SARS-CoV-2 epidemiology</article-title>. <source>Proc Natl Acad Sci USA</source><volume>118</volume>:<elocation-id>e2108395118</elocation-id>. doi:<pub-id pub-id-type="doi">10.1073/pnas.2108395118</pub-id>.<pub-id pub-id-type="pmid">34873059</pub-id></mixed-citation>
              </ref>
              <ref id="B9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Galipeau</surname><given-names>Y</given-names></string-name>, <string-name><surname>Siragam</surname><given-names>V</given-names></string-name>, <string-name><surname>Laroche</surname><given-names>G</given-names></string-name>, <string-name><surname>Marion</surname><given-names>E</given-names></string-name>, <string-name><surname>Greig</surname><given-names>M</given-names></string-name>, <string-name><surname>McGuinty</surname><given-names>M</given-names></string-name>, <string-name><surname>Booth</surname><given-names>RA</given-names></string-name>, <string-name><surname>Durocher</surname><given-names>Y</given-names></string-name>, <string-name><surname>Cuperlovic-Culf</surname><given-names>M</given-names></string-name>, <string-name><surname>Bennett</surname><given-names>SAL</given-names></string-name>, <string-name><surname>Crawley</surname><given-names>AM</given-names></string-name>, <string-name><surname>Giguere</surname><given-names>PM</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>C</given-names></string-name>, <string-name><surname>Langlois</surname><given-names>MA</given-names></string-name></person-group>. <year>2021</year>. <article-title>Relative ratios of human seasonal coronavirus antibodies predict the efficiency of cross-neutralization of SARS-CoV-2 spike binding to ACE2</article-title>. <source>EBioMedicine</source><volume>74</volume>:<fpage>103700</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103700</pub-id>.<pub-id pub-id-type="pmid">34861490</pub-id></mixed-citation>
              </ref>
              <ref id="B10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nasrallah</surname><given-names>GK</given-names></string-name></person-group>. <year>2022</year>. <article-title>Do preexisting antibodies against seasonal coronaviruses have a protective role against SARS-CoV-2 infections and impact on COVID-19 severity?</article-title><source>EBioMedicine</source><volume>76</volume>:<fpage>103831</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ebiom.2022.103831</pub-id>.<pub-id pub-id-type="pmid">35081490</pub-id></mixed-citation>
              </ref>
              <ref id="B11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sagar</surname><given-names>M</given-names></string-name>, <string-name><surname>Reifler</surname><given-names>K</given-names></string-name>, <string-name><surname>Rossi</surname><given-names>M</given-names></string-name>, <string-name><surname>Miller</surname><given-names>NS</given-names></string-name>, <string-name><surname>Sinha</surname><given-names>P</given-names></string-name>, <string-name><surname>White</surname><given-names>LF</given-names></string-name>, <string-name><surname>Mizgerd</surname><given-names>JP</given-names></string-name></person-group>. <year>2021</year>. <article-title>Recent endemic coronavirus infection is associated with less-severe COVID-19</article-title>. <source>J Clin Invest</source><volume>131</volume>:<elocation-id>e143380</elocation-id>. doi:<pub-id pub-id-type="doi">10.1172/JCI143380</pub-id>.<pub-id pub-id-type="pmid">32997649</pub-id></mixed-citation>
              </ref>
              <ref id="B12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lin</surname><given-names>CY</given-names></string-name>, <string-name><surname>Wolf</surname><given-names>J</given-names></string-name>, <string-name><surname>Brice</surname><given-names>DC</given-names></string-name>, <string-name><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name><surname>Locke</surname><given-names>M</given-names></string-name>, <string-name><surname>Cherry</surname><given-names>S</given-names></string-name>, <string-name><surname>Castellaw</surname><given-names>AH</given-names></string-name>, <string-name><surname>Wehenkel</surname><given-names>M</given-names></string-name>, <string-name><surname>Crawford</surname><given-names>JC</given-names></string-name>, <string-name><surname>Zarnitsyna</surname><given-names>VI</given-names></string-name>, <string-name><surname>Duque</surname><given-names>D</given-names></string-name>, <string-name><surname>Allison</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Allen</surname><given-names>EK</given-names></string-name>, <string-name><surname>Brown</surname><given-names>SA</given-names></string-name>, <string-name><surname>Mandarano</surname><given-names>AH</given-names></string-name>, <string-name><surname>Estepp</surname><given-names>JH</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>C</given-names></string-name>, <string-name><surname>Molina-Paris</surname><given-names>C</given-names></string-name>, <string-name><surname>Schultz-Cherry</surname><given-names>S</given-names></string-name>, <string-name><surname>Tang</surname><given-names>L</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>PG</given-names></string-name>, <string-name><surname>McGargill</surname><given-names>MA</given-names></string-name>, <collab>SJTRC Study Team</collab></person-group>. <year>2022</year>. <article-title>Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response</article-title>. <source>Cell Host Microbe</source><volume>30</volume>:<fpage>83</fpage>–<lpage>96.e4</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chom.2021.12.005</pub-id>.<pub-id pub-id-type="pmid">34965382</pub-id></mixed-citation>
              </ref>
              <ref id="B13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Estcourt</surname><given-names>L</given-names></string-name>, <string-name><surname>Callum</surname><given-names>J</given-names></string-name></person-group>. <year>2022</year>. <article-title>Convalescent plasma for Covid-19—making sense of the inconsistencies</article-title>. <source>N Engl J Med</source><volume>386</volume>:<fpage>1753</fpage>–<lpage>1754</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMe2204332</pub-id>.<pub-id pub-id-type="pmid">35507487</pub-id></mixed-citation>
              </ref>
              <ref id="B14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sullivan</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Gebo</surname><given-names>KA</given-names></string-name>, <string-name><surname>Shoham</surname><given-names>S</given-names></string-name>, <string-name><surname>Bloch</surname><given-names>EM</given-names></string-name>, <string-name><surname>Lau</surname><given-names>B</given-names></string-name>, <string-name><surname>Shenoy</surname><given-names>AG</given-names></string-name>, <string-name><surname>Mosnaim</surname><given-names>GS</given-names></string-name>, <string-name><surname>Gniadek</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Fukuta</surname><given-names>Y</given-names></string-name>, <string-name><surname>Patel</surname><given-names>B</given-names></string-name>, <string-name><surname>Heath</surname><given-names>SL</given-names></string-name>, <string-name><surname>Levine</surname><given-names>AC</given-names></string-name>, <string-name><surname>Meisenberg</surname><given-names>BR</given-names></string-name>, <string-name><surname>Spivak</surname><given-names>ES</given-names></string-name>, <string-name><surname>Anjan</surname><given-names>S</given-names></string-name>, <string-name><surname>Huaman</surname><given-names>MA</given-names></string-name>, <string-name><surname>Blair</surname><given-names>JE</given-names></string-name>, <string-name><surname>Currier</surname><given-names>JS</given-names></string-name>, <string-name><surname>Paxton</surname><given-names>JH</given-names></string-name>, <string-name><surname>Gerber</surname><given-names>JM</given-names></string-name>, <string-name><surname>Petrini</surname><given-names>JR</given-names></string-name>, <string-name><surname>Broderick</surname><given-names>PB</given-names></string-name>, <string-name><surname>Rausch</surname><given-names>W</given-names></string-name>, <string-name><surname>Cordisco</surname><given-names>ME</given-names></string-name>, <string-name><surname>Hammel</surname><given-names>J</given-names></string-name>, <string-name><surname>Greenblatt</surname><given-names>B</given-names></string-name>, <string-name><surname>Cluzet</surname><given-names>VC</given-names></string-name>, <string-name><surname>Cruser</surname><given-names>D</given-names></string-name>, <string-name><surname>Oei</surname><given-names>K</given-names></string-name>, <string-name><surname>Abinante</surname><given-names>M</given-names></string-name>, <string-name><surname>Hammitt</surname><given-names>LL</given-names></string-name>, <string-name><surname>Sutcliffe</surname><given-names>CG</given-names></string-name>, <string-name><surname>Forthal</surname><given-names>DN</given-names></string-name>, <string-name><surname>Zand</surname><given-names>MS</given-names></string-name>, <string-name><surname>Cachay</surname><given-names>ER</given-names></string-name>, <string-name><surname>Raval</surname><given-names>JS</given-names></string-name>, <string-name><surname>Kassaye</surname><given-names>SG</given-names></string-name>, <string-name><surname>Foster</surname><given-names>EC</given-names></string-name>, <string-name><surname>Roth</surname><given-names>M</given-names></string-name>, <string-name><surname>Marshall</surname><given-names>CE</given-names></string-name>, <string-name><surname>Yarava</surname><given-names>A</given-names></string-name>, <string-name><surname>Lane</surname><given-names>K</given-names></string-name>, <string-name><surname>McBee</surname><given-names>NA</given-names></string-name>, <string-name><surname>Gawad</surname><given-names>AL</given-names></string-name>, <string-name><surname>Karlen</surname><given-names>N</given-names></string-name>, <string-name><surname>Singh</surname><given-names>A</given-names></string-name>, <string-name><surname>Ford</surname><given-names>DE</given-names></string-name>, <string-name><surname>Jabs</surname><given-names>DA</given-names></string-name>, <string-name><surname>Appel</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Shade</surname><given-names>DM</given-names></string-name></person-group>, <etal>et al</etal>. <year>2022</year>. <article-title>Early outpatient treatment for Covid-19 with convalescent plasma</article-title>. <source>N Engl J Med</source><volume>386</volume>:<fpage>1700</fpage>–<lpage>1711</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2119657</pub-id>.<pub-id pub-id-type="pmid">35353960</pub-id></mixed-citation>
              </ref>
              <ref id="B15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shoham</surname><given-names>S</given-names></string-name>, <string-name><surname>Bloch</surname><given-names>EM</given-names></string-name>, <string-name><surname>Casadevall</surname><given-names>A</given-names></string-name>, <string-name><surname>Hanley</surname><given-names>D</given-names></string-name>, <string-name><surname>Lau</surname><given-names>B</given-names></string-name>, <string-name><surname>Gebo</surname><given-names>K</given-names></string-name>, <string-name><surname>Cachay</surname><given-names>E</given-names></string-name>, <string-name><surname>Kassaye</surname><given-names>SG</given-names></string-name>, <string-name><surname>Paxton</surname><given-names>JH</given-names></string-name>, <string-name><surname>Gerber</surname><given-names>J</given-names></string-name>, <string-name><surname>Levine</surname><given-names>AC</given-names></string-name>, <string-name><surname>Naeim</surname><given-names>A</given-names></string-name>, <string-name><surname>Currier</surname><given-names>J</given-names></string-name>, <string-name><surname>Patel</surname><given-names>B</given-names></string-name>, <string-name><surname>Allen</surname><given-names>ES</given-names></string-name>, <string-name><surname>Anjan</surname><given-names>S</given-names></string-name>, <string-name><surname>Appel</surname><given-names>L</given-names></string-name>, <string-name><surname>Baksh</surname><given-names>S</given-names></string-name>, <string-name><surname>Blair</surname><given-names>PW</given-names></string-name>, <string-name><surname>Bowen</surname><given-names>A</given-names></string-name>, <string-name><surname>Broderick</surname><given-names>P</given-names></string-name>, <string-name><surname>Caputo</surname><given-names>CA</given-names></string-name>, <string-name><surname>Cluzet</surname><given-names>V</given-names></string-name>, <string-name><surname>Elena</surname><given-names>MC</given-names></string-name>, <string-name><surname>Cruser</surname><given-names>D</given-names></string-name>, <string-name><surname>Ehrhardt</surname><given-names>S</given-names></string-name>, <string-name><surname>Forthal</surname><given-names>D</given-names></string-name>, <string-name><surname>Fukuta</surname><given-names>Y</given-names></string-name>, <string-name><surname>Gawad</surname><given-names>AL</given-names></string-name>, <string-name><surname>Gniadek</surname><given-names>T</given-names></string-name>, <string-name><surname>Hammel</surname><given-names>J</given-names></string-name>, <string-name><surname>Huaman</surname><given-names>MA</given-names></string-name>, <string-name><surname>Jabs</surname><given-names>DA</given-names></string-name>, <string-name><surname>Jedlicka</surname><given-names>A</given-names></string-name>, <string-name><surname>Karlen</surname><given-names>N</given-names></string-name>, <string-name><surname>Klein</surname><given-names>S</given-names></string-name>, <string-name><surname>Laeyendecker</surname><given-names>O</given-names></string-name>, <string-name><surname>Karen</surname><given-names>L</given-names></string-name>, <string-name><surname>McBee</surname><given-names>N</given-names></string-name>, <string-name><surname>Meisenberg</surname><given-names>B</given-names></string-name>, <string-name><surname>Merlo</surname><given-names>C</given-names></string-name>, <string-name><surname>Mosnaim</surname><given-names>G</given-names></string-name>, <string-name><surname>Park</surname><given-names>HS</given-names></string-name>, <string-name><surname>Pekosz</surname><given-names>A</given-names></string-name>, <string-name><surname>Petrini</surname><given-names>J</given-names></string-name>, <string-name><surname>Rausch</surname><given-names>W</given-names></string-name>, <string-name><surname>Shade</surname><given-names>DM</given-names></string-name>, <string-name><surname>Shapiro</surname><given-names>JR</given-names></string-name>, <string-name><surname>Singleton</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Sutcliffe</surname><given-names>C</given-names></string-name></person-group>, <etal>et al</etal>. <year>2022</year>. <article-title>Transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection: a double-blinded, phase 2 randomized, controlled trial</article-title>. <source>Clin Infect Dis</source><fpage>ciac372</fpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciac372</pub-id>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
